Intellia Therapeutics, Inc. (NTLA) AI Stock Analysis

Intellia Therapeutics, Inc. is a genome editing company developing treatments using its proprietary CRISPR/Cas9 technology. Its in vivo pipeline includes NTLA-2001 in Phase 1 clinical trials for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema, alongside liver-focused programs for hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for acute myeloid leukemia and engineered cell therapies for oncology and autoimmune disorders. The company maintains development partnerships with Novartis Institutes for BioMedical Research, Regeneron Pharmaceuticals, Ospedale San Raffaele, and SparingVision SAS.

Intellia's annual revenue rose from $33.1M in FY2021 to $67.7M in FY2025, representing a 5-year compound annual growth rate of 3.1%. Despite the revenue growth, the company generated significant net losses, posting -$259.7M in FY2021, -$474.2M in FY2022, -$481.2M in FY2023, -$519.0M in FY2024, and -$412.7M in FY2025. In FY2025, operating margin stood at -651.7% and R&D expenses were $388.9M. For the latest quarter ended June 30, 2026, quarterly revenue decreased 46.2% year-over-year, bringing trailing twelve-month revenue to $59.5M with an operating margin of -1472.3%.

As of June 30, 2026, Intellia held $437.8M in cash and short-term investments alongside total debt of $73.4M, resulting in net cash of $364.3M. The company's current ratio was 6.65, and its debt-to-equity ratio stood at 0.10 against shareholders' equity of $727.7M. During FY2025, operating cash flow was -$348.9M, free cash flow was -$354.7M, and capital expenditures were $5.8M. Over the trailing 5-year period, the company's share count increased by 79.3%.

Intellia trades at a price-to-sales multiple of 26.9x and an enterprise value to revenue multiple of 23.0x, both well above the median of its US-listed Healthcare peers of 4.1x sales. Its price-to-book ratio is 2.4x. As of October 16, 2026, the stock was down 54.2% over the prior year and down 91.2% over five years, underperforming the S&P 500 benchmark gains of 16.8% and 83.0% over the identical respective periods.

Wall Street coverage on Intellia includes 9 Strong Buy, 1 Buy, 6 Hold, 2 Sell, and 2 Strong Sell recommendations. The mean price target is $23.11, representing a 102.4% premium over the October 16, 2026 closing price of $11.42. For the fiscal year ending December 31, 2026, analysts estimate revenue of $51.9M and an EPS of -$3.14. For the following fiscal year, 17 analysts project revenue of $126.3M and an EPS of -$2.56. The company beat EPS estimates in 3 of the last 4 quarters, with its next earnings report scheduled for November 5, 2026.

This page is an AI-written research summary of Intellia Therapeutics, Inc. (NTLA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NTLA income statement, NTLA balance sheet, NTLA key metrics, NTLA analyst forecast, NTLA chart. See the NTLA stock overview for the latest quote and news.